AbbVie expands board to 13, appoints Jennifer Davis and Susan Quaggin as directors

AbbVie Inc.

Board expanded from 11 to 13 directors; Jennifer Davis (Class II) and Susan Quaggin (Class III) appointed.
Davis is CEO, Health Care at Procter & Gamble; Quaggin is Irving S. Cutter Professor and Chair of Medicine at Northwestern.
Davis appointed to Nominations and Governance Committee; Quaggin to Public Policy and Sustainability Committee.
Board affirmatively determined both are independent under NYSE standards and AbbVie guidelines.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jennifer Davis

Class II director

ABBV · AbbVie Inc.

Effective: 2023-10-11
Filed: October 12, 2023, 7:59 PM ET

appointed Jennifer Davis as a Class II director

Appointed

Susan Quaggin

Class III director

ABBV · AbbVie Inc.

Effective: 2023-10-11
Filed: October 12, 2023, 7:59 PM ET

and Susan Quaggin as a Class III director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jennifer Davis was appointed as Class II director at AbbVie Inc..

Action: appointed
Role: Class II director

Exact text from the filing

appointed Jennifer Davis as a Class II director

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Susan Quaggin was appointed as Class III director at AbbVie Inc..

Action: appointed
Role: Class III director

Exact text from the filing

and Susan Quaggin as a Class III director

View on SEC.gov

AbbVie Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-108864

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.